GU Cancer ESMO 2025 Highlights: PSMAddition, Capitello-281, Potomac, Keynote-905, IMVigor011

In this episode of the Oncology Brothers podcast, we dive into the groundbreaking data presented at ESMO 2025, focusing on the GU landscape, particularly prostate and bladder cancer. Join us as we welcome Dr. Stephanie Berg, a GU medical oncologist from the Dana-Farber Cancer Institute, to discuss key studies and their implications for patient care.

Episode Highlights:

• ⁠PSMAddition: Explore the benefits of lutetium PSMA in metastatic hormone-sensitive prostate cancer, including improved radiographic progression-free survival when combined with ADT and ARPIs.
• Capitello-281: Highlights the use of Capivasertib in patients with PTEN loss, showing significant improvements in radiographic PFS.
• Potomac: Examining the role of durvalumab + BCG in high-risk non-muscle invasive bladder cancer, and the promising results from the Keynote 905 study involving enfortumab and pembrolizumab.
• IMVigor011: Delved into showcasing how ctDNA-guided therapy with atezolizumab can improve survival outcomes.

Stay tuned as we navigate the complexities of treatment options, side effects, and the importance of patient-centered decision-making in oncology. 

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights!

#ESMO2025 #GUOncology #LutetiumPSMA #Enfortumab #BladderCancer #ProstateCancer #OncologyBrothers